Antiretroviral Therapy for Treatment and Prevention: Beyond Daily Oral Therapy - A New Frontier

Martin H. Markowitz MD
Anna and George Bobolas Professor of Clinical Research and Infectious Diseases
Aaron Diamond AIDS Research Center at Columbia University Irving Medical Center
Hammer Health Sciences, New York, NY



CME VIDEOTop of page

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenter:Top of page

Martin Markowitz is a graduate of Stanford Medical School and completed his postgraduate training in Hematology/Oncology at Cornell Medical College and Infectious Diseases at New York University. Dr. Markowitz has worked at the Aaron Diamond AIDS Research Center (ADARC) since 1992 and currently holds the positions of Clinical Director and Staff Investigator. His seminal work in elucidating the dynamics of HIV-1 infection in vivo along with his mentor Dr. David Ho and colleagues at the Aaron Diamond AIDS Research Center formed the scientific foundation for triple combination therapy. In addition, his research interests have included the pathogenesis and treatment of acute HIV-1 infection, the fitness and transmission of drug-resistant HIV-1, and investigations of numerous novel antiretroviral agents as well as pathogenesis-based interventional trials. He was among the first to discuss HIV-1 cure, and perform trials of therapeutic vaccination and passive immunization as adjuncts to combination antiretroviral therapy.

Learning Objectives: Top of page

At the completion of this educational session, learners will:

  • Illustrate current recommendations for cART for HIV prevention and treatment and the need for alternatives to daily oral therapy.
  • Review recent data for long acting cabotegravir (CAB LA) and long acting rilpivirine (RPV LA) for the treatment of HIV infection.Review recent data for long acting cabotegravir (CAB LA) and long acting rilpivirine (RPV LA) for the treatment of HIV infection.
  • Present preclinical and clinical data of Cabotegravir LA and preclinical data of Islatravir for the prevention of HIV infection.
  • Discuss broadly neutralizing antibodies (bNAbs) for the treatment and prevention of HIV infection.

CME Information:Top of page

This CME activity has approved for AMA PRA Category 1 Credit™ for June 4, 2020 as a live activity.  This activity will also be available as an enduring activity from June 13, 2020, through June 22, 2023. The target audience is all physicians, NPs and PAs involved or interested in HIV education. This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians. The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity. - Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose. - Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. - Dr. Martin H. Markowitz (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Grant funding from TaiMed, Merck, and GSK; Consultant to TaiMed, and Thera; Speaker’s bureau for Gilead. Dr. Markowitz will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Evaluation

You must be logged in to post a comment. Login | Register